How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

2,585 results for

Uterine Fibroid

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

101. Assessment of Safety and Efficacy of Vilaprisan in Subjects With Uterine Fibroids

Assessment of Safety and Efficacy of Vilaprisan in Subjects With Uterine Fibroids Assessment of Safety and Efficacy of Vilaprisan in Subjects With Uterine Fibroids - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding (...) more. Assessment of Safety and Efficacy of Vilaprisan in Subjects With Uterine Fibroids (ASTEROID 7) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT03699176 Recruitment Status : Active, not recruiting First Posted : October 8, 2018 Last Update Posted : March 21, 2019 Sponsor: Bayer Information

2018 Clinical Trials

102. Spontaneous complete regression of large uterine fibroid after the second vaginal delivery: Case report. Full Text available with Trip Pro

Spontaneous complete regression of large uterine fibroid after the second vaginal delivery: Case report. Fibroids are common, hormone-dependent, benign uterine tumors. It is estimated that they occur in 20% to 40% of women during their reproductive years. The prevalence of fibroids among pregnant women is 10.7%. Most fibroids do not increase in size during pregnancy. Pregnancy has a variable and unpredictable effect on fibroid growth. The influence of pregnancy on uterine fibroid size still (...) remains unclear. Researchers evaluating fibroids have reported an inverse association between parity and fibroids, suggestive of a protective effect. Pregnancies that occur while fibroids are small would be protective; whereas pregnancies occurring before fibroid development or after the tumors reach some critical size would not be protective. Herein, the case of a woman with a large uterine fibroid that was spontaneously regressed after a second successful vaginal delivery is reported. To our

2018 Medicine

103. Ulipristal acetate decreases transforming growth factor β3 serum and tumor tissue concentrations in patients with uterine fibroids. Full Text available with Trip Pro

Ulipristal acetate decreases transforming growth factor β3 serum and tumor tissue concentrations in patients with uterine fibroids. To evaluate and compare transforming growth factor β3 (TGF-β3) serum concentration in patients with uterine fibroids (UFs) without hormone treatment, treated with ulipristal acetate (UPA), and controls; to evaluate TGF-β3 concentrations in UF tissue in patients without hormone treatment and those treated with UPA; and to evaluate the correlations of age and body

2018 Fertility and Sterility

104. A Study to Assess the Safety and Efficacy of Vilaprisan in Japanese Subjects With Uterine Fibroids and Heavy Menstrual Bleeding

A Study to Assess the Safety and Efficacy of Vilaprisan in Japanese Subjects With Uterine Fibroids and Heavy Menstrual Bleeding A Study to Assess the Safety and Efficacy of Vilaprisan in Japanese Subjects With Uterine Fibroids and Heavy Menstrual Bleeding - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached (...) the maximum number of saved studies (100). Please remove one or more studies before adding more. A Study to Assess the Safety and Efficacy of Vilaprisan in Japanese Subjects With Uterine Fibroids and Heavy Menstrual Bleeding (ASTEROID 8) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT03476928 Recruitment

2018 Clinical Trials

105. Association Between Vitamin D and the Development of Uterine Fibroids

Association Between Vitamin D and the Development of Uterine Fibroids Association Between Vitamin D and the Development of Uterine Fibroids - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Association (...) Between Vitamin D and the Development of Uterine Fibroids The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. of clinical studies and talk to your health care provider before participating. Read our for details. ClinicalTrials.gov Identifier: NCT03584529 Recruitment Status : Not yet recruiting First Posted : July 12, 2018 Last Update Posted : September 5, 2018

2018 Clinical Trials

106. Association Between Vitamin D and the Risk of Uterine Fibroids

Association Between Vitamin D and the Risk of Uterine Fibroids Association Between Vitamin D and the Risk of Uterine Fibroids - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Association Between Vitamin D (...) and the Risk of Uterine Fibroids (ABVDATROUF) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. of clinical studies and talk to your health care provider before participating. Read our for details. ClinicalTrials.gov Identifier: NCT03586947 Recruitment Status : Not yet recruiting First Posted : July 16, 2018 Last Update Posted : September 5, 2018 See Sponsor

2018 Clinical Trials

107. Identification and bioinformatics analysis of overlapping differentially expressed genes in depression, papillary thyroid cancer and uterine fibroids Full Text available with Trip Pro

Identification and bioinformatics analysis of overlapping differentially expressed genes in depression, papillary thyroid cancer and uterine fibroids It is hypothesized that there may be common characteristics between the genetic regulatory networks of different diseases. To identify these potential similarities, analysis of overlapping differentially expressed genes (DEGs) in several diseases, which are believed to be associated in traditional Chinese medicine (TCM) was performed (...) in the present study. The gene expression profiles associated with depression, papillary thyroid carcinoma (PTC) and uterine fibroids (UF) were preliminarily analyzed using Gene Expression Omnibus 2R tools. Gene Ontology enrichment analysis, Kyoto Encyclopedia of Genes and Genomes pathway analysis and protein-protein interaction network analysis of the overlapping DEGs in depression, PTC and UF was performed. The results indicated that multiple genes, including activating transcription factor 3 and WSC

2018 Experimental and therapeutic medicine

108. Clinical outcomes and health care utilization pre- and post-laparoscopic radiofrequency ablation of symptomatic fibroids and laparoscopic myomectomy: a randomized trial of uterine-sparing techniques (TRUST) in Canada Full Text available with Trip Pro

Clinical outcomes and health care utilization pre- and post-laparoscopic radiofrequency ablation of symptomatic fibroids and laparoscopic myomectomy: a randomized trial of uterine-sparing techniques (TRUST) in Canada The objective of this study was to compare laparoscopic ultrasound-guided radiofrequency ablation of fibroids (Lap-RFA) and laparoscopic myomectomy in terms of 1) health care utilization and 2) serious complication rates. The secondary objectives were comparison of subject (...) responses to validated symptom and quality-of-life questionnaires. We hypothesized that Lap-RFA health care utilization and clinical outcomes would not be worse than those of laparoscopic myomectomy in the aggregate.Post-market, randomized, prospective, multicenter, longitudinal, non-inferiority interventional comparative evaluation of health care utilization and clinical outcomes in premenopausal women with symptomatic uterine fibroids who desired uterine conservation was conducted. Both procedures

2018 ClinicoEconomics and Outcomes Research: CEOR Controlled trial quality: uncertain

109. Burden, Prevalence, and Treatment of Uterine Fibroids: A Survey of U.S. Women Full Text available with Trip Pro

Burden, Prevalence, and Treatment of Uterine Fibroids: A Survey of U.S. Women Most women will experience uterine fibroids by the age of 50, yet few data exist describing the overall patient experience with fibroids. The objective of this population-based survey was to characterize symptom burden, patient awareness, and treatment decision-making for fibroids, including a comparison among women of varying backgrounds.Women (≥18 years) were recruited via email from GfK KnowledgePanel® (...) , a representative panel of US households, or identified with opt-in consumer panels. The Uterine Fibroid Symptom and Health-Related Quality of Life (UFS-QOL) questionnaire and Aberdeen Menorrhagia Severity Scale (AMSS) were included.Eligible women were grouped into three cohorts: "at-risk" (symptoms suggestive of fibroids without clinical diagnosis, n = 300), "diagnosed" (n = 871), and fibroid-related "hysterectomy" (n = 272). Cohort and intracohort race/ethnicity and income analyses revealed differences

2018 Journal of Women's Health

110. Current medical treatment of uterine fibroids Full Text available with Trip Pro

Current medical treatment of uterine fibroids Uterine fibroids (leiomyomas or myomas), benign monoclonal tumors, are the most common benign tumors in women. Heavy or prolonged menstrual bleeding, abnormal uterine bleeding, resultant anemia, pelvic pain, infertility, and/or recurrent pregnancy loss are generally associated with uterine fibroids. Although curative treatment of this tumor relies on surgical therapies, medical treatments are considered the first-line treatment to preserve fertility (...) and avoid or delay surgery. The aim of this review is to provide available and emerging medical treatment options for symptomatic uterine fibroids. Literature review and consensus of expert opinion. Many uterine fibroids are asymptomatic and require no intervention, although it is advisable to follow-up patients to document stability in size and growth. Fibroid-associated symptoms include heavy menstrual bleeding and pain or pelvic discomfort. The association between infertility and fibroids increases

2018 Obstetrics & gynecology science

111. Aromatase Plus GnRH Analogue Versus Ulippristal Acetate in Uterine Fibroids

Aromatase Plus GnRH Analogue Versus Ulippristal Acetate in Uterine Fibroids Aromatase Plus GnRH Analogue Versus Ulippristal Acetate in Uterine Fibroids - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more (...) . Aromatase Plus GnRH Analogue Versus Ulippristal Acetate in Uterine Fibroids The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. of clinical studies and talk to your health care provider before participating. Read our for details. ClinicalTrials.gov Identifier: NCT03421639 Recruitment Status : Recruiting First Posted : February 5, 2018 Last Update Posted

2018 Clinical Trials

112. The Role of Fibroblast Activation in Uterine Fibroid

The Role of Fibroblast Activation in Uterine Fibroid The Role of Fibroblast Activation in Uterine Fibroid - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. The Role of Fibroblast Activation in Uterine Fibroid (...) by (Responsible Party): Nashwa Elmaghrby, Assiut University Study Details Study Description Go to Brief Summary: Uterine fibroids (UFs), also called uterine leiomyomas or myomas, are steroid hormone-responsive, benign tumors of the smooth muscle compartment (myometrium) of the uterus. They are the most common neoplasm affecting women in their reproductive age. It is estimated that up to 77% of women develop UF in their life. UFs are one of the leading causes of hospitalisations for gynaecological disorders

2018 Clinical Trials

113. Assess Safety and Efficacy of Vilaprisan in Subjects With Uterine Fibroids (ASTEROID 4)

Assess Safety and Efficacy of Vilaprisan in Subjects With Uterine Fibroids (ASTEROID 4) Assess Safety and Efficacy of Vilaprisan in Subjects With Uterine Fibroids (ASTEROID 4) - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies (...) before adding more. Assess Safety and Efficacy of Vilaprisan in Subjects With Uterine Fibroids (ASTEROID 4) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT03400956 Recruitment Status : Active, not recruiting First Posted : January 17, 2018 Last Update Posted : March 7, 2019 Sponsor: Bayer Information

2018 Clinical Trials

114. Assess Safety and Efficacy of Vilaprisan in Subjects With Uterine Fibroids (ASTEROID 3)

Assess Safety and Efficacy of Vilaprisan in Subjects With Uterine Fibroids (ASTEROID 3) Assess Safety and Efficacy of Vilaprisan in Subjects With Uterine Fibroids (ASTEROID 3) - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies (...) before adding more. Assess Safety and Efficacy of Vilaprisan in Subjects With Uterine Fibroids (ASTEROID 3) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT03400943 Recruitment Status : Active, not recruiting First Posted : January 17, 2018 Last Update Posted : March 5, 2019 Sponsor: Bayer Information

2018 Clinical Trials

115. OCL 500 Treatment of Women With Symptomatic Uterine Fibroids

OCL 500 Treatment of Women With Symptomatic Uterine Fibroids OCL 500 Treatment of Women With Symptomatic Uterine Fibroids - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. OCL 500 Treatment of Women (...) With Symptomatic Uterine Fibroids The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT03427671 Recruitment Status : Active, not recruiting First Posted : February 9, 2018 Last Update Posted : February 22, 2019 Sponsor: IMBiotechnologies Ltd. Information provided by (Responsible Party): IMBiotechnologies Ltd. Study

2018 Clinical Trials

116. Vilaprisan in women with uterine fibroids: the randomized phase 2b ASTEROID 1 study. Full Text available with Trip Pro

Vilaprisan in women with uterine fibroids: the randomized phase 2b ASTEROID 1 study. To assess the safety and efficacy of four vilaprisan doses (0.5-4.0 mg) in women with uterine fibroids.Randomized, double-blind, placebo-controlled, multicenter trial.Ninety-eight centers in 12 countries.Women aged 18-50 years with uterine fibroids and heavy menstrual bleeding were randomized equally to oral vilaprisan at 0.5, 1.0, 2.0, or 4.0 mg or placebo once daily.Treatment for 12 weeks, 24-week follow (...) of heavy menstrual bleeding associated with uterine fibroids. Daily oral treatment with vilaprisan 0.5-4.0 mg was well tolerated, and vilaprisan 2.0 mg once daily has been selected for further investigation.NCT02131662.Copyright © 2018 The Authors. Published by Elsevier Inc. All rights reserved.

2018 Fertility and Sterility Controlled trial quality: predicted high

117. Study of Relugolix With Estradiol and Norethindrone Acetate in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids

Study of Relugolix With Estradiol and Norethindrone Acetate in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids Study of Relugolix With Estradiol and Norethindrone Acetate in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have (...) reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Study of Relugolix With Estradiol and Norethindrone Acetate in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT03751124

2018 Clinical Trials

118. Uterine Fibroids: From Molecular Oncology to Reproduction Full Text available with Trip Pro

Uterine Fibroids: From Molecular Oncology to Reproduction 30250848 2019 02 12 2019 02 15 2314-6141 2018 2018 BioMed research international Biomed Res Int Uterine Fibroids: From Molecular Oncology to Reproduction. 6284875 10.1155/2018/6284875 Tinelli Andrea A 0000-0001-8426-8490 Department of Gynecology and Obstetrics, Division of Experimental Endoscopic Surgery, Imaging, Minimally Invasive Therapy and Technology, Vito Fazzi Hospital, Lecce, Italy. Laboratory of Human Physiology, Phystech BioMed (...) of Pisa, Italy. eng Editorial 2018 09 03 United States Biomed Res Int 101600173 IM Female Humans Leiomyoma genetics metabolism pathology Reproduction Uterine Neoplasms genetics metabolism pathology 2018 07 08 2018 07 11 2018 9 26 6 0 2018 9 27 6 0 2019 2 13 6 0 epublish 30250848 10.1155/2018/6284875 PMC6140000

2018 BioMed research international

119. Safety after extended repeated use of ulipristal acetate for uterine fibroids. Full Text available with Trip Pro

Safety after extended repeated use of ulipristal acetate for uterine fibroids. To assess long term safety of extended repeated 3-month courses of ulipristal acetate (UPA) 10 mg/day, for up to 8 courses, with focus on endometrial and laboratory safety parameters.This long-term, multi-center, open-label cohort, follow up study consisted of up to 8 consecutive 3-month courses of daily UPA 10 mg, each separated by a drug free period of 2 spontaneous menstrual bleeds. Sixty-four pre-menopausal women (...) , with moderate to severe symptomatic uterine myoma(s) and heavy bleeding were enrolled and were studied for approximately 4 years. The main outcome measures were endometrial histology, laboratory parameters and general safety.All data was reported in a descriptive manner with no formal statistical comparisons. In the 64 women, non-physiological changes (mostly cyst formation, epithelial and vascular changes) in endometrial histology at screening and after treatment courses 4 and 8 were observed in 18.0

2017 PLoS ONE

120. Systematic evaluation and meta-analysis of the efficacy of different forms of guizhi fuling pills in the treatment of uterine fibroids

Systematic evaluation and meta-analysis of the efficacy of different forms of guizhi fuling pills in the treatment of uterine fibroids Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration

2020 PROSPERO

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>